• Sie sind hier:
  • Forschung .
  • Molekulare und Translationale Kardiologie

c

W3 Professur für Molekulare und Translationale Kardiologie

Die meisten Patienten mit Herzinfarkt haben heute eine gute Prognose, wenn sie das Krankenhaus rechtzeitig erreichen. Patienten mit großem Infarkt entwickeln jedoch häufig eine chronische Herzmuskelschwäche (Herzinsuffizienz). In der Molekularen und Translationalen Kardiologie untersuchen wir die Mechanismen, die zur Entwicklung einer Herzinsuffizienz nach Infarkt führen, mit dem Ziel, bessere diagnostische (Biomarker) und therapeutische Strategien für unsere Patienten zu entwickeln (Zelltherapie, Proteintherapie, kleine Moleküle).

 

Curriculum Vitae | Prof. Dr. Kai Christoph Wollert

 Professional Career

  • 1991
    Medical Licensing Exam (Staatsexamen)

  • 1992
    U.S. American Medical State Examination (ECFMG)

  • 1991 – 1993
    Intern (Arzt im Praktikum), Dept. of Cardiology and Angiology, University of Freiburg

  • 1993 – 1995
    Postdoctoral Fellow, Center for Molecular Genetics, University of California, San Diego

  • 1995 – 1996
    Resident (Assistenzarzt), Dept. of Cardiology and Angiology, University of Freiburg

  • 1996 – 2002
    Resident (Assistenzarzt), Dept. of Cardiology and Angiology, Hannover Medical School

  • Since 2002
    Clinical Fellow (Oberarzt), Dept. of Cardiology and Angiology, Hannover Medical School

  • 2000
    Board Certification in Internal Medicine

  • 2004
    Board Certification in Cardiology

  • 2015
    Certification in Interventional Cardiology

 

Scientific Career

  • 1991
    Dr. med. (MD)

  • 2001
    Habilitation

  • 2001 – 2007
    Assistant Professor (Privatdozent), Hannover Medical School

  • 2007 – 2010
    Associate (W2) Professor for Cardiac Cell Therapy, Hannover Medical School

  • 2010
    Offer for Full (W3) Professorship and Head of the Dept. of Cardiology and Angiology at the University of Gießen, Germany (refused)

  • Since 2010
    Full (W3) Professor for Molecular and Translational Cardiology, Hannover Medical School

Awards
  • 1987
    German National Academic Foundation (Studienstiftung des Deutschen Volkes)

  • 1996
    Young Investigators Award, European Society of Cardiology, Working Group Drug Therapy in Cardiology and Cardiovascular Pharmacotherapy

  • 2004
    Karl-Ludwig-Neuhaus Prize of the German Cardiac Society

  • 2006
    Albert-Fraenkel-Prize of the German Cardiac Society

  • 2006
    Innovation Prize of German Academic Medicine (Innovationspreis der Deutschen Hochschulmedizin)

  • 2007
    Arthur-Weber-Prize of the German Cardiac Society

  • 2007
    Jan Brod Prize (Gesellschaft der Freunde der MHH)

  • 2009
    European Society of Cardiology, Council for Basic Cardiovascular Science
    Outstanding Achievement Award

  • 2015
    1st Poster Prize of the of the German Cardiac Society to Dr. Mortimer Korf-Klingebiel (Annual Meeting in Mannheim)

News
Selected Publications
  • Reboll MR, Korf-Klingebiel M, Klede S, Polten F, Brinkmann E, Reimann I, Schönfeld HJ, Bobadilla M, Faix J, Kensah G, Gruh I, Klintschar M, Gaestel M, Niessen HW, Pich A, Bauersachs J, Gogos JA, Wang Y, Wollert KC. Endoplasmic reticulum membrane protein complex subunit 10 (EMC10) is a bone marrow-derived angiogenic growth factor promoting tissue repair after myocardial infarction. Circulation. 2017; Circulation. 2017;136(19):1809-23. https://www.ncbi.nlm.nih.gov/pubmed/28931551
  • Wollert KC, Meyer GP, Müller-Ehmsen J, Tschöpe C, Bonarjee V, Larsen AI, May AE, Empen K, Chorianopoulos E, Tebbe U, Waltenberger J, Mahrholdt H, Ritter B, Pirr J, Fischer D, Korf-Klingebiel M, Arseniev L, Heuft HG, Brinchmann JE, Messinger D, Hertenstein B, Ganser A, Katus HA, Felix SB, Gawaz MP, Dickstein K, Schultheiss HP, Ladage D, Greulich S, Bauersachs J. Intracoronary autologous bone marrow cell transfer after myocardial infarction: The BOOST-2 randomised placebo-controlled clinical trial. Eur Heart J. 2017;38(39):2936-43. https://www.ncbi.nlm.nih.gov/pubmed/28431003
  • Wollert KC, Kempf T, Wallentin L. Growth differentiation factor 15 as a biomarker in cardiovascular disease. Clin Chem. 2017;63:140-151. https://www.ncbi.nlm.nih.gov/pubmed/28062617
  • Wollert KC, Kempf T, Giannitsis E, Bertsch T, Braun SL, Maier H, Reim M, Christenson RH. An automated assay for growth differentiation factor 15. J Appl Lab Med. 2017;1:510-52. http://jalm.aaccjnls.org/content/1/5/510
  • Haddad S, Wang Y, Galy B, Korf-Klingebiel M, Hirsch V, Baru AM, Rostami F, Reboll MR, Heineke J, Flögel U, Groos S, Renner A, Toischer K, Zimmermann F, Engeli S, Jordan J, Bauersachs J, Hentze MW, Wollert KC, Kempf T. Iron-regulatory proteins secure iron availability in cardiomyocytes to prevent heart failure. Eur Heart J. 2017 Feb 1;38(5):362-372. https://www.ncbi.nlm.nih.gov/pubmed/27545647
  • Korf-Klingebiel M, Reboll MR, Klede S, Brod T, Pich A, Polten F, Napp CL, Bauersachs J, Ganser A, Brinkmann E, Reimann I, Kempf T, Niessen HW, Mizrahi J, Schönfeld H-J, Iglesias A, Bobadilla M, Wang Y, Wollert KC. Myeloid-derived growth factor (C19orf10) mediates cardiac repair following myocardial infarction. Nat Med. 2015; 21:140-149. https://www.ncbi.nlm.nih.gov/pubmed/25581518
  • Wang TJ*, Wollert KC*, Larson MG, Coglianese E, McCabe EL, Cheng S, Ho JE, Fradley MG, Ghorbani A, Xanthakis V, Kempt T, Benjamin EJ, Levy D, Vasan RS, Januzzi JL. Prognostic utility of novel biomarkers of cardiovascular stress: the Framing Heart Study. Circulation. 2012;126:1596-604, *equal contribution. https://www.ncbi.nlm.nih.gov/pubmed/22907935
  • Kempf T, Zarbock A, Widera C, Butz S, Stadtmann A, Rossaint J, Bolomini-Vittori M, Korf-Klingebiel M, Napp LC, Hansen B, Kanwischer A, Bavendiek U, Beutel G, Hapke M, Sauer MG, Laudana C, Hogg N, Vestweber D, Wollert KC. GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat Med. 2011;17:581-588. https://www.ncbi.nlm.nih.gov/pubmed/21516086
  • Korf-Klingebiel M, Kempf T, Schlüter KD, Willenbockel C, Brod T, Heineke J, Schmidt VJ, Jantzen F, Brandes RP, Sugden PH, Drexler H, Molkentin JD, Wollert KC. Conditional transgenic expression of fibroblast growth factor 9 in the adult mouse heart reduces heart failure mortality after myocardial infarction. Circulation. 2011;123:504-514. https://www.ncbi.nlm.nih.gov/pubmed/21262993
  • Bonaca MP, Morrow DA, Braunwald E, Cannon CP, Jiang S, Breher S, Sabatine MS, Kempf T, Wallentin L, Wollert KC. Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome. Observations from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol. 2011;31:203-210. https://www.ncbi.nlm.nih.gov/pubmed/20966402
  • Anand IS, Kempf T, Rector TS, Tapken H, Allhoff T, Jantzen F, Kuskowski M, Cohn JN, Drexler H, Wollert KC. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. Circulation. 2010;122:1387-1395. https://www.ncbi.nlm.nih.gov/pubmed/20855664
  • Wollert KC, Drexler H. Cell therapy for the treatment of coronary heart disease: a critical appraisal. Nature Reviews Cardiol. 2010;7:204-215. https://www.ncbi.nlm.nih.gov/pubmed/20177405
     
s